Advertisement

Pharmacological Treatment of Non-suicidal Self-injury and Eating Disorders

  • Paul L. Plener
  • Ulrike M. Schulze
Chapter

Abstract

There is very little evidence for the psychopharmacological treatment of NSSI and eating disorders and no evidence for the treatment of a combination of both. However, often patients with NSSI and eating disorders present with comparable problems with regard to emotional dysregulation, the need to control urges (e.g., to cut or to binge or purge), and the need to treat comorbid mental disorders or psychiatric symptoms such as depression or anxiety. Based on the recent literature, this chapter aims to summarize the available literature and give recommendations for the psychopharmacological treatment of these conditions. Due to the limited evidence that is available for this kind of treatment, we strongly recommend to use psychopharmacological treatment only in addition to psychotherapeutic interventions.

Keywords

Anorexia Nervosa Borderline Personality Disorder Eating Disorder Bulimia Nervosa Dialectical Behavior Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

AA

Atypical antipsychotics

BPD

Borderline personality disorder

CBT

Cognitive behavioral therapy

DBT

Dialectical behavioral therapy

NDD

Neurodevelopmental disorders

NSSI

Non-suicidal self-injury

OCD

Obsessive-compulsive disorder

PDD

Pervasive developmental disorder

PRN

“Pro re nata” medication

RCT

Randomized controlled trial

SSRI

Selective serotonin reuptake inhibitor

TCA

Tricyclic antidepressant

References

  1. Abraham, P. F., & Calabrese, J. R. (2008). Evidence-based pharmacologic treatment of borderline personality disorder: A shift from SSRIs to anticonvulsants and atypical antipsychotics? Journal of Affective Disorders, 111, 21–30.CrossRefPubMedGoogle Scholar
  2. Aigner, M., Treasure, J., Kaye, W., Kasper, S., & WFSBP Task Force On Eating Disorders. (2011). World ion of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World Journal of Biological Psychiatry, 12, 400–443.CrossRefPubMedGoogle Scholar
  3. Attia, E., & Schroeder, L. (2005). Pharmacologic treatment of anorexia nervosa: Where do we go from here? International Journal of Eating Disorders, 37, S60–S63.CrossRefPubMedGoogle Scholar
  4. Bellino, S., Paradiso, E., & Bogetto, F. (2005). Oxcarbazepine in the treatment of borderline personality disorder: A pilot study. Journal of Clinical Psychiatry, 66, 1111–1115.CrossRefPubMedGoogle Scholar
  5. Bloom, C. M., & Holly, S. (2011). Toward new avenues in the treatment of nonsuicidal self-injury. Journal Pharmacy Practice, 24, 472–477.CrossRefGoogle Scholar
  6. Brent, D. A. (2004). Antidepressants and pediatric depression—The risk of doing nothing. New England Journal of Medicine, 351, 1598–1601.CrossRefPubMedGoogle Scholar
  7. Brent, D. A., Emslie, G. J., Clarke, G. N., Asarnow, J., Spirito, A., Ritz, L., et al. (2009). Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry, 166, 418–426.CrossRefPubMedGoogle Scholar
  8. Brent, D. A., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Keller, M., et al. (2008). Switching to another SSRI or to venlafaxine with or without cognitive behavioural therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. Journal of the American Medical Association, 299, 901–913.CrossRefPubMedGoogle Scholar
  9. Burgess, S., Geddes, J., Hawton, K., Townsend, E., Jamison, K., & Goodwin, G. (2001). Lithium for maintenance treatment of mood disorders. Cochrane Database of Systematic Reviews, 3, CD003013.PubMedGoogle Scholar
  10. Cassano, P., Lattanzi, L., Pini, S., Dell’Osso, L., Battistini, G., & Cassano, G. B. (2001). Topiramate for self-mutilation in a patient with borderline personality disorder. Bipolar Disorders, 3, 161.CrossRefPubMedGoogle Scholar
  11. Chengappa, K. N. R., Ebeling, T., Kang, J. S., Levine, J., & Parepally, H. (1999). Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. Journal of Clinical Psychiatry, 60, 477–484.CrossRefPubMedGoogle Scholar
  12. Cipriani, A., Pretty, H., Hawton, K., & Geddes, J. R. (2005). Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: A systematic review of randomized trials. American Journal of Psychiatry, 162, 1805–1819.CrossRefPubMedGoogle Scholar
  13. Claudino, A. M., Slva de Lima, M., Hay, P. P. J., Bacaltchuk, J., Schmidt, U. U. S., & Treasure, J. (2009). Antidepressants for anorexia nervosa (review). The Cochrane Library, 1, 1–47.Google Scholar
  14. Cordàs, T. A., Tavares, H., Calderoni, D. M., Stump, G. V., & Ribeiro, R. B. (2006). Oxcarbazepine for self-mutilating bulimic patients. International Journal of Neuropsychopharmacology, 9, 769–771.CrossRefPubMedGoogle Scholar
  15. Correll, C. U. (2007). Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: A systematic review and pooled analysis of short term trials. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 687–700.CrossRefPubMedGoogle Scholar
  16. Corwin, R. L., Boan, J., Peters, K. F., & Ulbrecht, J. S. (2012). Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study. Behavioral Pharmacology, 23, 616–625.CrossRefGoogle Scholar
  17. Cowdry, R. W., & Gardner, D. L. (1988). Pharmacotherapy for borderline personality disorder. Archives of General Psychiatry, 45, 111–119.CrossRefPubMedGoogle Scholar
  18. de la Fuente, J. M., & Lotstra, F. (1994). A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacol, 4, 479–486.CrossRefGoogle Scholar
  19. Dickstein, D. P., Towbin, K. E., Van Der Veen, J. W., Rich, B. A., Brotman, M. A., Knopf, L., et al. (2009). Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation. Journal of Child and Adolescent Psychopharmacology, 19, 61–73.CrossRefPubMedGoogle Scholar
  20. Donovan, S., Clayton, A., Beeharry, M., Jones, S., Kirk, C., Waters, K., et al. (2000). Deliberate self-harm following antidepressant drugs. British Journal of Psychiatry, 177, 551–556.CrossRefPubMedGoogle Scholar
  21. Faris, P. L., Kim, S. W., Meller, W. H., Goodale, R. L., Oakman, S. A., Hofbauer, R. D., Marshall, A. M., Daughters, R. S., Banerjee-Stevens, D., Eckert, E. D., & Hartman, B. K. (2000). Effect of decreasing afferent vagal activity with Ondansetron on symptoms of bulimia nervosa: A randomised, double-blind trial. Lancet, 355, 792–797.CrossRefPubMedGoogle Scholar
  22. Fassino, S., Leombruni, P., Daga, G., Brustolin, A., Migliaretti, G., Cavallo, F., & Rovera, G. (2002). Efficacy of citalopram in anorexia nervosa: A pilot study. European Neuropsychopharmacology, 12, 453–459.CrossRefPubMedGoogle Scholar
  23. Flament, M. F., Bissada, H., & Spettigue, W. (2012). Evidence-based pharmacotherapy of eating disorders. International Journal of Neuropsychopharmacology, 15, 189–207.CrossRefPubMedGoogle Scholar
  24. Forbes, D., & Pearsons, H. (2012). Essential fatty acids: Food for mind and body. Acta Paediatrica, 101, 806–810.CrossRefGoogle Scholar
  25. Garland, M. R., Hallahan, B., McNamara, M., Carney, P. A., Grimes, H., Hibbeln, J. R., et al. (2007). Lipids and essential fatty acids in patients presenting with self-harm. British Journal of Psychiatry, 190, 112–117.CrossRefPubMedGoogle Scholar
  26. Gibbons, R. D., Brown, H., Hur, K., Davis, J. M., & Mann, J. J. (2012). Suicidal thoughts and behaviour with antidepressant treatment. Archives of General Psychiatry, 69, 580–587.CrossRefPubMedGoogle Scholar
  27. Good, C. R. (2006). Adjunctive Quetiapine targets self-harm behaviors in adolescent females with major depressive disorder. Journal of Child and Adolescent Psychopharmacology, 16, 235–236.CrossRefPubMedGoogle Scholar
  28. Goodyer, I., Dubicka, B., Wilkinson, P., Kelvin, R., Roberts, C., Byford, S., et al. (2007). Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: Randomised controlled trial. British Medical Journal, 335, 142–150.CrossRefPubMedGoogle Scholar
  29. Greetfeld, M., Cuntz, U., & Vorderholzer, U. (2012). Pharmacotherapy for anorexia nervosa and bulimia nervosa. Fortschritte Der Neurologie Psychiatrie, 80, 9–16.CrossRefPubMedGoogle Scholar
  30. Griengl, H., Sendera, A., & Dantendorfer, K. (2001). Naltrexone as a treatment of self-injurious behavior: A case report. Acta Psychiatrica Scandinavica, 103, 234–236.CrossRefPubMedGoogle Scholar
  31. Grootens, K. P., & Verkes, R. J. (2005). Emerging evidence for the use of atypical antipsychotics in borderline personality disorder. Pharmacopsychiatry, 38, 20–23.CrossRefPubMedGoogle Scholar
  32. Groschwitz, R. C., & Plener, P. L. (2012). The neurobiology of non-suicidal self-injury (NSSI): A review. Suicidology Online, 3, 24–32.Google Scholar
  33. Haleem, D. J. (2012). Serotonin neurotransmission in anorexia nervosa. Behavioural Pharmacology, 23, 478–495.CrossRefPubMedGoogle Scholar
  34. Hallahan, B., Hibbeln, J. R., Davis, J. M., & Garland, M. R. (2007). Omega-3 fatty acid supplementation in patients with recurrent self-harm. British Journal of Psychiatry, 190, 118–122.CrossRefPubMedGoogle Scholar
  35. Harper, G. (2012). Psychopharmacological treatment. In B. W. Walsh (Ed.), Treating self-injury. A practical guide (2nd ed., pp. 195–203). New York: The Guilford Press.Google Scholar
  36. Hawton, K., Townsend, E., Arensmann, E., Gunnel, D., Hazell, P., House, A., & van Heeringen, K. (2009). Psychosocial and pharmacological treatments for deliberate self harm. Cochrane Database of Systematic Reviews, 1999(4). Art. No.: CD001764. doi: 10.1002/14651858.CD001764.
  37. Herpertz, S., Hagenah, U., Vocks, S., von Wietersheim, J., Cuntz, U., & Zeeck, A. (2011). Clinical practice guideline: The diagnosis and treatment of eating disorders. Deutsches Ärzteblatt International, 108, 678–685.PubMedGoogle Scholar
  38. Hilger, E., Barnas, C., & Kasper, S. (2003). Quetiapine in the treatment of borderline personality disorder. World Journal Biological Psychiatry, 4, 42–44.CrossRefGoogle Scholar
  39. Holtkamp, K., Konrad, K., Kaiser, N., Ploenes, Y., Heussen, N., Grzella, I., & Herpertz-Dahlmann, B. (2005). A retrospective study of SSRI treatment in adolescent anorexia nervosa: Insufficient evidence for efficacy. Journal of Psychiatric Research, 39, 303–310.CrossRefPubMedGoogle Scholar
  40. Ingenhoven, T., Lafay, P., Rinne, T., Passchierj, J., & Duivenvoorden, H. (2010). Effectiveness of pharmacotherapy for severe personality disorders: Meta-analysis of randomized controlled trials. Journal of Clinical Psychiatry, 71, 14–25.CrossRefPubMedGoogle Scholar
  41. Isacsson, J., Holmgren, P., & Ahlner, J. (2005). Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: A controlled forensic database study of 14 857 suicides. Acta Psychiatrica Scandinavica, 111, 286–290.CrossRefPubMedGoogle Scholar
  42. Katz, L. Y., & Fotti, S. (2005). The role of behavioral analysis in the pharmacotherapy of emotionally-dysregulated problem behaviors. Child and Adolescent Psychopharmacology News, 10, 1–5.CrossRefGoogle Scholar
  43. Kaye, W. H., Frank, G. K., Bailer, U. F., & Henry, S. E. (2005). Neurobiology of anorexia nervosa: Clinical implications of alterations of the function of serotonin and other neuronal systems. International Journal of Eating Disorders, 37, S15–S19.CrossRefPubMedGoogle Scholar
  44. Kaye, W. H., Gendall, K., & Strober, M. (1998). Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biological Psychiatry, 44, 825–838.CrossRefPubMedGoogle Scholar
  45. Kishi, T., Kafantaris, V., Sunday, S., Sheridan, E. M., & Correll, C. U. (2012). Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. Journal of Clinical Psychiatry, 73, e757–e766.CrossRefPubMedGoogle Scholar
  46. Kleindienst, N., Bohus, M., Ludäscher, P., Limberger, M. F., Kuenkele, K., Ebner-Priemer, U. W., et al. (2008). Motives for non-suicidal self-injury among women with borderline personality disorder. Journal of Nervous and Mental Disease, 196, 230–236.CrossRefPubMedGoogle Scholar
  47. Klonsky, E. D. (2007). The functions of deliberate self-injury: A review of the evidence. Clinical Psychology Review, 27, 226–239.CrossRefPubMedGoogle Scholar
  48. Kumra, S., Oberstar, J. V., Sikich, L., Findling, R. L., McClellan, J. M., Vinogradov, S., et al. (2008). Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophrenia Bulletin, 34, 60–71.CrossRefPubMedGoogle Scholar
  49. Libal, G., & Plener, P. L. (2008). Pharmakologische Therapie des selbstverletzenden Verhaltens im Jugendalter. In R. Brunner & F. Resch (Eds.), Borderline-Störungen und selbstverletzendes Verhalten bei Jugendlichen (pp. 165–195). Göttingen: Vandenhoeck & Ruprecht.Google Scholar
  50. Libal, G., Plener, P. L., Ludolph, A. G., & Fegert, J. M. (2005). Ziprasidone as a weight-neutral treatment alternative in the treatment of self-injurious behavior in adolescent females. Child and Adolescent Psychopharmacology News, 10, 1–6.CrossRefGoogle Scholar
  51. Linehan, M. M., McDavid, J. D., Brown, M. Z., Sayrs, J. H., & Gallop, R. J. (2008). Olanzapine plus dialectical behaviour therapy for women with high irritability who meet criteria for borderline personality disorder: A double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry, 69, 999–1005.CrossRefPubMedGoogle Scholar
  52. Markovitz, P. J., Calabrese, J. R., Schulz, C., & Meltzer, H. Y. (1991). Fluoxetine in the treatment of borderline and schizotypal personality disorders. American Journal of Psychiatry, 18, 1064–1067.Google Scholar
  53. Masters, K. J. (2008). Anti-suicidal and self-harm properties of lithium carbonate. CNS Spectrums, 13, 109–110.PubMedGoogle Scholar
  54. McGee, M. D. (1997). Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. Journal of Clinical Psychiatry, 58, 32–33.CrossRefPubMedGoogle Scholar
  55. Mehler-Wex, C., Romanos, M., Kirchheiner, J., & Schulze, U. M. (2008). Atypical anti-psychotics in severe anorexia nervosa in children and adolescents—Review and case reports. European Eating Disorders Review, 16, 100–108.CrossRefPubMedGoogle Scholar
  56. Mercer, D., Douglass, A. B., & Links, P. S. (2009). Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: Effectiveness for depression and anger symptoms. Journal of Personality Disorders, 23, 156–174.CrossRefPubMedGoogle Scholar
  57. Nickel, M. K., Loew, T. H., & Pedrosa, G. F. (2007). Aripiprazole in treatment of borderline patients, part II: An 18-month follow-up. Psychopharmacology, 191, 1023–1026.CrossRefPubMedGoogle Scholar
  58. Nickel, M. K., Muehlbacher, M., Nickel, K., Kettler, C., Gil, F. P., Bachler, E., et al. (2006). Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind, placebo-controlled study. American Journal of Psychiatry, 163, 833–838.CrossRefPubMedGoogle Scholar
  59. Nixon, M. K., Cloutier, P. F., & Aggarwal, S. (2002). Affect regulation and addictive aspects of repetitive self-injury in hospitalized adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1333–1341.CrossRefPubMedGoogle Scholar
  60. Nose, M., Cipriani, A., Biancosino, B., Grassi, L., & Barbui, C. (2006). Efficacy of pharmacotherapy against core traits of borderline personality disorder: Meta-analysis of randomized controlled trials. International Clinical Psychopharmacology, 21, 345–353.CrossRefPubMedGoogle Scholar
  61. Osuch, E. A., & Payne, G. W. (2009). Neurobiological perspectives on self-injury. In M. K. Nixon & N. L. Heath (Eds.), Self-injury in youth (pp. 79–111). New York: Routledge.Google Scholar
  62. Owen, C., Rees, A. M., & Parker, G. (2008). The role of fatty acids in the development and treatment of mood disorders. Current Opinion in Psychiatry, 21, 19–24.CrossRefPubMedGoogle Scholar
  63. Parikh, M. S., Kolevzon, A., & Hollander, E. (2008). Psychopharmacology of aggression in children and adolescents with autism: A critical review of efficacy and tolerability. Journal of Child and Adolescent Psychopharmacology, 18, 157–178.CrossRefPubMedGoogle Scholar
  64. Pies, R. W., & Popli, A. P. (1995). Self-injurious behavior: Pathophysiology and implications for treatment. Journal of Clinical Psychiatry, 56, 580–588.PubMedGoogle Scholar
  65. Plener, P. L., Libal, G., Fegert, J. M., & Kölch, M. G. (2013). Psychopharmacological treatment of non-suicidal self-injury. Nervenheilkunde, 32, 38–41.Google Scholar
  66. Plener, P. L., Libal, G., & Nixon, M. K. (2009). Use of medication in the treatment of nonsuicidal self-injury in youth. In M. K. Nixon & N. L. Heath (Eds.), Self-injury in youth (pp. 275–309). New York: Routledge.Google Scholar
  67. Powers, P. S., Klabunde, M., & Kaye, W. (2012). Double-blind placebo-controlled trial of quetiapine in anorexia nervosa. European Eating Disorders Review, 20, 331–334.CrossRefPubMedGoogle Scholar
  68. Roberts, N. (2003). Adolescent self-mutilatory behavior: Psychopharmacological treatment. Child and Adolescent Psychopharmacology News, 8, 10–12.CrossRefGoogle Scholar
  69. Roth, A. S., Ostroff, R. B., & Hoffman, E. R. (1996). Naltrexone as a treatment for repetitive self-injurious behaviour: An open-label trial. Journal of Clinical Psychiatry, 57, 233–237.PubMedGoogle Scholar
  70. Rothschild, A. J., Shindul-Rothschild, J. A., Viguera, A., Murray, M., & Brewster, S. (2000). Comparison of the frequency of behavioural disinhibition on alprazolam, clonazepam, or no benzodiazepine in hospitalized psychiatric patients. Journal of Clinical Psychopharmacology, 20, 7–11.CrossRefPubMedGoogle Scholar
  71. Sandman, C. A. (1990/1991). The opiate hypothesis in autism and self-injury. Journal of Child and Adolescent Psychopharmacology, 1, 237–248.CrossRefGoogle Scholar
  72. Sandman, C. A. (2009). Psychopharmacologic treatment of nonsuicidal self-injury. In M. K. Nock (Ed.), Understanding nonsuicidal self-injury. Origins, assessment, and treatment (pp. 291–323). Washington, DC: American Psychological Association.CrossRefGoogle Scholar
  73. Sandman, C. A., Hetrick, W. P., Taylor, D. V., Barron, J. L., Touchette, P., Lott, I., et al. (1993). Naltrexone reduces self-injury and improves learning. Experimental and Clinical Psychopharmacology, 1, 242–258.CrossRefGoogle Scholar
  74. Scahill, L., & Koenig, K. (1999). Pharmacotherapy in children and adolescents with pervasive developmental disorders. Journal of Child and Adolescent Psychiatric Nursing, 12, 41–43.CrossRefPubMedGoogle Scholar
  75. Schulz, S. C., Zanarini, M. C., Bateman, A., Bohus, M., Detke, H. C., Trzaskoma, Q., et al. (2008). Olanzapine for the treatment of borderline personality disorder: Variable dose 12-week randomised double-blind placebo-controlled study. British Journal of Psychiatry, 193, 485–492.CrossRefPubMedGoogle Scholar
  76. Sher, L., & Stanley, B. (2009). Biological models of nonsuicidal self-injury. In M. K. Nock (Ed.), Understanding nonsuicidal self-injury. Origins, assessment, and treatment (pp. 99–117). Washington, DC: American Psychological Association.CrossRefGoogle Scholar
  77. Simpson, E. B., Yen, S., Costello, E., Rosen, K., Begin, A., Pistorello, J., et al. (2004). Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 379–385.CrossRefPubMedGoogle Scholar
  78. Sonne, S., Rubey, R., Brady, K., Malcolm, R., & Morris, T. (1996). Naltrexone treatment of self-injurious thoughts and behaviours. Journal of Nervous and Mental Disease, 184, 192–195.CrossRefPubMedGoogle Scholar
  79. Swenne, I., Rosling, A., Tengblad, S., & Vessby, B. (2011). Omega-3 polyunsaturated essential fatty acids are associated with depression in adolescents with eating disorders and weight loss. Acta Paediatrica, 100, 1610–1615.CrossRefPubMedGoogle Scholar
  80. Symons, F. J., Thompson, A., & Rodriguez, M. C. (2004). Self-injurious behaviour and the efficacy of naltrexone treatment: A quantitative synthesis. Mental Retardation and Developmental Disabilities Research Reviews, 10, 193–200.CrossRefPubMedGoogle Scholar
  81. Teicher, M. H., Glod, C. A., & Cole, J. O. (1993). Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety, 8, 186–212.CrossRefPubMedGoogle Scholar
  82. Thompson, T., Hackenberg, T., Cerutti, D., Baker, D., & Axtell, S. (1994). Opioid antagonist effects on self-injury in adults with mental retardation: Response from and location as determinants of medication effects. American Journal of Mental Retardation, 99, 85–102.PubMedGoogle Scholar
  83. Trunko, M. E., Schwartz, T. A., Duvvuri, V., & Kaye, W. H. (2011). Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: Case reports. International Journal of Eating Disorders, 44, 269–275.CrossRefPubMedGoogle Scholar
  84. Verkes, R. J., Van der Mast, R. C., Hengeveld, M. W., Tuyl, J. P., Zwinderman, A. H., & Van Kempen, G. M. (1998). Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. American Journal of Psychiatry, 155, 543–547.PubMedGoogle Scholar
  85. Whittington, C. J., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., & Boddington, E. (2004). Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. The Lancet, 36, 1341–1345.CrossRefGoogle Scholar
  86. Zanarini, M. C., & Frankenburg, F. R. (2003). Omega-3 fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. American Journal of Psychiatry, 160, 167–169.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Child and Adolescent Psychiatry and PsychotherapyUniversity of UlmUlmGermany

Personalised recommendations